Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2012 • 2015 ACR/ARHP Annual Meeting
TNF Confers Pathogenic Memory in Synovial Fibroblasts Via Chromatin Remodeling, NF-Kb-Dependent Transcription and MAPK-Mediated mRNA Stabilization
Konstantinos Loupasakis¹, Christopher Sohn², Lionel B. Ivashkiv³ and George D. Kalliolias², ¹Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: We investigated mechanisms driving pathogenic behavior of synovial fibroblasts (FLS) in rheumatoid arthritis (RA). Methods: FLS from RA patients (1987 classification criteria) were extracted.…
Abstract Number: 544 • 2015 ACR/ARHP Annual Meeting
IL-6 May Have an Important Role in the Resistance to Anti-TNF Therapies of Human T-Lymphotropic Virus Type 1 (HTLV-1) Positive Rheumatoid Arthritis (RA) Patients; HTLV-1 Infected Cells Activate the Inflammatory Responses of RA Synovial Fibroblasts
Kunihiko Umekita¹, Shunichi Miyauchi¹, Kazuyoshi Kubo¹, Kazumi Umeki¹, Hajime Nomura¹, Mao Komura¹, Koushou Iwao¹, Ichiro Takajo¹, Yasuhiro Nagatomo¹, Toshihiko Hidaka² and Akihiko Okayama¹, ¹Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan, ²Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan
Background/Purpose: We reported that human T-lymphotropic virus type 1 (HTLV-1) positive patients with rheumatoid arthritis (RA) had higher inflammation and greater resistance to anti-TNF treatment…
Abstract Number: 2102 • 2015 ACR/ARHP Annual Meeting
Higher Persistence and Adherence with Combination Therapy with Tumor Necrosis Factor Inhibitor+Methotrexate Combination Versus Triple Therapy in US Veterans with Rheumatoid Arthritis
Brian Sauer¹, Chia-Chen Teng², Jianwei Leng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Bradley S. Stolshek⁶, Derek Tang⁶ and Grant W. Cannon⁷, ¹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Internal Medicine Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA, ⁷Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT

Background/Purpose: Randomized controlled trials in RA have reported efficacy with both triple therapy (methotrexate [MTX] + hydroxychloroquine [HCQ] + sulfasalazine [SSZ]) and tumor necrosis factor…
Abstract Number: 582 • 2015 ACR/ARHP Annual Meeting
Biological Drugs Dose Tapering in Inflammatory Rheumatic Diseases: 2 Year Results at Basurto University Hospital
Juan María Blanco-Madrigal¹, Maria Luz Garcia Vivar¹, Catalina Gomez Arango¹, Olaia Fernández Berrizbeitia¹, Clara Perez Velasquez¹, Ignacio Torre Salaberri², Jose Francisco Garcia Llorente³, Eva Galindez-Agirregoikoa⁴, Esther Ruiz Lucea¹ and Iñigo Gorostiza⁵, ¹Rheumatology, Basurto University Hospital, Bilbao, Spain, ²Rheumaytology, Basurto University Hospital, Bilbao, Spain, ³Rheumatology, Basurto University Hospital., Bilbao, Spain, ⁴Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ⁵Research Department, BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain
Background/Purpose: Last years, biological dose tapering in patients with inflammatory diseases has become a routine clinical practice. Since 2011 we are applying a dose reduction…
Abstract Number: 2546 • 2015 ACR/ARHP Annual Meeting
Targeting Synovial Fibroblasts By the Intra-Articular Delivery of microRNA-140-3p and -5p Ameliorates Experimental Autoimmune Arthritis
Chrong-Reen Wang¹, Jia-Shiou Peng², Shih-Yao Chen³, Chao-Liang Wu⁴ and Ai-Li Shiau⁵, ¹Rheum/Immun Sec/Int Med Dept, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ²Institute of Basic Medical Sciences, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ³Internal Medicine, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ⁴Biochemistry and Molecular Biology, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ⁵Microbiology and Immunology, College of Medicine, National Cheng Kung University, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan
Background/Purpose: Synovial fibroblasts (SF) with aberrant expression of microRNAs (miRNA) are critical pathogenic regulators of rheumatoid joint, and studies examining the effect of overexpressing or…
Abstract Number: 1038 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha and Peptidylarginine Deiminase 4 in Lung and Joint Inflammation
Mandar Bawadekar¹, Annette Gendron-Fitzpatrick², Thomas F. Warner³, Lennart K.A. Lundblad⁴, Paul Thompson⁵ and Miriam A. Shelef^1,6, ¹Medicine, University of Wisconsin, Madison, WI, ²Comparative Pathology Laboratory of the Research Animal Resources Center and Pathobiological Sciences, University of Wisconsin, Madison, WI, ³Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, ⁴Medicine, The University of Vermont, Burlington, VT, ⁵University of Massachusetts, Worcester, MA, ⁶Medicine, William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: The relationship between lung and joint inflammation in rheumatoid arthritis is poorly understood. About 10% of people with rheumatoid arthritis develop interstitial lung disease…
Abstract Number: 2564 • 2015 ACR/ARHP Annual Meeting
Nuclear Receptor 4A2 Is Selectively Upregulated in the Human TNF-Alpha Transgenic Model of Rheumatoid Arthritis
Jackeline Araujo, Cullen Lilley and Kimberlee Mix, Biological Sciences, Loyola University New Orleans, New Orleans, LA
Background/Purpose: The orphan nuclear receptor 4A2 (NR4A2 / NURR1) is emerging as a critical transcription factor in chronic inflammatory joint diseases. We have demonstrated elevated…
Abstract Number: 1039 • 2015 ACR/ARHP Annual Meeting
The Safety and Effect on Disease Activity of Tocilizumab in Combination with MTX Versus Tocilizumab Monotherapy in Patients with Mild to Moderate RA: An Attempt to Optimise the Treatment Response
Burkhard Leeb^1,2, Raimund Lunzer³, Peter Fasching⁴, Manfred Herold⁵, O. Zamani⁶, Winfried Graninger⁷ and OPTIMISE trial Investigators, ¹2nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria, ²Department of Clinical Rheumatology, Karl Landsteiner Society, Stockerau, Austria, ³Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, ⁴Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, ⁵Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, ⁶Rheumazentrum Favoriten, Wien, Austria, ⁷Rheumatology and Immunology, Medical University of Graz, Graz, Austria
Background/Purpose: An Austrian multi-center study of the effect on disease activity and the safety of Tocilizumab (TCZ) in combination with Methotrexate (MTX) versus TCZ Monotherapy…
Abstract Number: 2566 • 2015 ACR/ARHP Annual Meeting
Novel Therapeutic Compound Tuftsin-Phosphorylcholine Attenuate Collagen Induced Arthritis
Tomer Bashi¹, Miri Blank¹, Jasna Omersel², Alexander Volkov³, Iris Barshack³ and Yehuda Shoenfeld¹, ¹Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ²Faculty of pharmacy, University of Ljublijana, Ljublijana, Slovenia, ³Sheba Medical Center, Institute of Pathology, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel
Background/Purpose: Treatment with helminthes and ova from helminthes, improved clinical findings of several autoimmune diseases in patients and in animal models. We aimed to decipher…
Abstract Number: 2487 • 2014 ACR/ARHP Annual Meeting
Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis
V. Strand¹, R. Riese², R. Gerber², D. Gruben², A.G. Bushmakin², E.Y. Mahgoub³ and G. Wallenstein², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we describe health care resource utilization (HCRU) and work…
Abstract Number: 1462 • 2014 ACR/ARHP Annual Meeting
Cadherin-11 mRNA Expression in the Peripheral Blood of Rheumatoid Arthritis Patients As a Marker of Active Polyarthritis
Petros P. Sfikakis¹, Panagiotis F. Christopoulos^1,2, Aristeidis G. Vaiopoulos^1,2, Kalliopi Fragkiadaki¹, Christina Katsiari³, Violetta Kapsimali⁴, George Lallas¹, Panayiotis Panayiotidis⁴, Pinelopi Korkopoulou⁵ and Michael Koutsilieris², ¹First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ²Department of Physiology, Athens University Medical School, Athens, Greece, ³Department of Rheumatology, School of Health Sciences, University of Thessaly, Larissa, Greece, ⁴Department of Microbiology, Athens University Medical School, Athens, Greece, ⁵Department of Pathology, Athens University Medical School, Athens, Greece
Background/Purpose: Human rheumatoid arthritis synovial fibroblasts (RASF) implanted subcutaneously in immunodeficient mice trans-migrate through the vasculature and drive the progression from oligo- to poly-articular disease.…
Abstract Number: 461 • 2014 ACR/ARHP Annual Meeting
Comprehensive Summary of the Efficacy and Safety of Tofacitinib 5mg Twice Daily in Patients with Rheumatoid Arthritis and an Inadequate Response to Disease-Modifying Antirheumatic Drugs
P. Bird¹, W. Bensen², B. El-Zorkany³, J. Kaine⁴, B.H. Manapat-Reyes⁵, V. Pascual-Ramos⁶, D. Witcombe⁷, A. Anisfeld⁸, K. Soma⁹, R. Zhang⁹ and K. Thirunavukkarasu⁷, ¹Combined Rheumatology Practice, Sydney, Australia, ²St. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada, ³Department of Rheumatology, Cairo University, Cairo, Egypt, ⁴Sarasota Arthritis Research Center, Sarasota, FL, ⁵Section of Rheumatology, Department of Medicine, University of the Philippines - Philippine General Hospital, Manila, Philippines, ⁶Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁷Pfizer Australia, Sydney, Australia, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib has been approved in the US and other countries at the recommended dose 5 mg BID in patients (pts) with rheumatoid arthritis (RA) and…
Abstract Number: 2480 • 2014 ACR/ARHP Annual Meeting
Is there a Difference in the Effectiveness in the Treatment of Rheumatoid Arthritis with Rituximab when Using a Dose of 1 or 2 Grams per Cycle? a Systematic Review
Ana M. Ortiz¹, María Piedad Rosario², Carmen Martínez² and Isidoro González-Alvaro¹, ¹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain
Background/Purpose: Since the description of the efficacy of rituximab (RTX) in treating patients with rheumatoid arthritis (RA), the use of this drug has been extended.…
Abstract Number: 1196 • 2014 ACR/ARHP Annual Meeting
Inflammation Develops in a Toll-like Receptor 9-Independent Manner in Experimental Arthritis and Rheumatoid Arthritis
Julie Mussard¹, Matthieu Ribon¹, Gaelle Clavel², Marie-Christophe Boissier³ and Patrice Decker¹, ¹INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, ²Fondation Ophtalmologique A. De Rothschild, Paris cedex 19, France, ³INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité, Bobigny, France
Background/Purpose Rheumatoid arthritis (RA) is an inflammatory disease of unknown etiology. Toll-like receptor (TLR) 9 recognizes pathogen-derived DNA and even self DNA under certain circumstances.…
Abstract Number: 460 • 2014 ACR/ARHP Annual Meeting
Analysis of Non-Melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Program
Jeffrey R. Curtis¹, E.B. Lee², G. Martin³, X. Mariette⁴, K.K. Terry⁵, Y. Chen⁶, J. Geier⁷, J. Andrews⁵, M. Kaur⁶, K. Kwok⁷ and C. Nduaka⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Seoul National University College of Medicine, Seoul, South Korea, ³Dermatology and Laser Center of Maui, Kihei, HI, ⁴Paris-Sud University, Paris, France, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The incidence of non-melanoma skin cancer (NMSC) in the tofacitinib…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].